GlycoPse | Manufacturing rare and complex glycans

The challenge

Biological relevance exists. Scalable supply does not.

The molecules matter.

Vaccines, infant and medical nutrition and microbiome science all depend on defined glycan structures.

The barrier is technical.

These structures resist both chemical synthesis and conventional fermentation. Routes that exist today deliver milligrams, not reproducible, costed material.

Nothing downstream happens.

Without supply, applications cannot be tested, formulations cannot be optimised and products cannot be developed.

Supply is the rate-limiting step for many biologically validated molecules.

Our approach

Biology to make what chemistry cannot.

GlycoPse uses industrial biotechnology to produce glycans that are impractical to make by chemical synthesis. Our proprietary approach is designed for reproducible, scalable and costed supply from the start.

Engineered biology

Microorganisms engineered to build complex sugar structures with the precision of nature.

Designed for scale

Processes developed with industrial manufacturing in mind, not as laboratory demonstrations.

Quality built in

Analytics and purification developed alongside production, so every lot is defined and characterised.

One platform, many glycans

Capabilities designed to carry from one rare glycan to the next.

Programs

Create the supply layer before the market exists.

Lead programs · Antimicrobial resistance

Rare bacterial surface sugars

Rare nine-carbon sugars on the surface of drug-resistant bacteria, and promising antigens for glycoconjugate vaccines. Access today is limited to research quantities.

On critical-priority pathogens

Present on Acinetobacter baumannii, a WHO critical-priority pathogen. Synthetic conjugates have produced protective immune responses in animal vaccine studies.

Recognised by the immune system

Found in the surface polysaccharides of a growing number of pathogenic bacteria, and recognised by antibodies in pooled human serum.

Extending the architecture

Complex human milk oligosaccharides

The same capabilities apply to structurally complex human milk oligosaccharides with a strong scientific rationale in early-life nutrition, where homogeneous material remains difficult to obtain.

Beyond these, we see a wider family of rare glycans that the architecture could reach over time.

The absence of a mature market is a consequence of the supply bottleneck, not a weakness of the molecules.

How we work with partners

What changes hands, and with whom.

Area

Who we serve

What we provide

Path

Rare antigen sugars

Glycan researchers, then vaccine development and CMC groups

Defined, evaluation-grade material

Material›Evaluation›Development partnership›Licensing

Complex HMOs

Nutrition and pharmaceutical ingredient partners

Manufacturing route, then material

Route›Qualification›Supply or partnership

Team

Industrial glycan experience, applied to a new class of molecules.

GlycoPse is founded by specialists who have spent their careers taking complex carbohydrates from the bench to commercial manufacture.

Carbohydrate chemistry and IP

Decades of work on complex sugars and their manufacture, and the intellectual property around them.

Industrial biotechnology

Years of building biological production processes for complex glycans in industry.

Process and scale-up

Bringing specialty glycan processes from the laboratory to commercial scale.

We are not asking anyone to believe the platform already exists. We are building the work that can prove it does.

Contact

Let's talk.

We are currently raising our pre-seed round. We would like to hear from investors, vaccine and nutrition developers, glycan researchers and future team members.

contact@glycopse.com

InvestorsVaccine developersNutrition partnersResearchersFuture colleagues